achema+world+wide+news+1 2008

8/4/2019 Achema+World+Wide+News+1 2008

1/21

1/2008

ACHEMA 2009:exciting conference topics


2/21

L

N e w sWORLDWIDE

Luckily, technologies are not shares. Their future can be predicted more

easily and precisely than that of share prices. But those who hold thetechnologies of the future need not worry about their share prices. If youare looking for the technology of tomorrow, youll find it in the develop-ment laboratories of today. But who has the time to visit all the labora-tories of the world? Who knows them all? Who gains admission every-where? The chemical industry and its affiliated process industries pos-sess a far more efficient trend barometer, a secure navigation system forthe road to success:ACHEMA.4,000 companies from 50 countries and numerous researchinstitutes vir-tually bring their laboratories to Frankfurt am Main for one week everythreeyears.Almost200,000people, leading scientistsand engineersfrom100of the worldscountries,meet up here. ACHEMAis theworldsbiggesthub for new ideas that design and put their markon the futureof process

technology. No shares are traded here its about more. This is whereknowledge is exchanged and converted into a force that designs thefuture. Decisions on the future are made exactly here, with the gates tosuccess wide open.The current stocks of fossil raw materials are far bigger than those in theyear of the first oil crisis in 1973. The community, however, has recog-nized that we endanger the worlds climate if we completely convert ourfossil resources into carbon dioxide.The chemical process industries bearthe responsibility for the worlds carbon cycle. Renewable raw materialsand energies as well as more efficient processes of their use are there-fore the topic of next years special show at ACHEMA.We are already today looking forward to your participation in ACHEMA2009,which takes place from 11th 15th Mayin Frankfurt am Main,andare convinced that you will not miss this opportunity.

Yours sincerely,

Prof. Gerhard KreysaChief Executive of DECHEMA e.V.

Shaping the future


3/21

Contents

14

12

10

8

20

22

3

18

23

5

Cover: fotolia.de; [M]-Michaela Schenk

Editors Page

News developments in pumps andcompressors using Ionic Liquids

Nanofiltration comes toorganic solvents

Implementation of the Globally

Harmonized System in the EU What are the changes?

Drug discovery and development:contract research and

manufacturing in India

Singapores chemicals industry

on the fast track

Selling pump energy savings

Integrated Technology RoadmapAutomation 2015+ published

UK aims to optimizebioscience opportunities

ACHEMA 2009:brisk exhibitors demand and

exciting conference topics

International conferences

organized by DECHEMA

Imprint

16

23


4/21

IIonic Liquids (ILs) are a new class of chemical substances having emergedin recent years in chemical research. Per definition, Ionic Liquids are or-ganic salts with a melting point below 100C. They consist of ions only,but this definition is different from the classic definition of molten salts.The latter are high-melting, highly viscous, and highly corrosive liquids,while ILs are liquid at usually much lower temperatures,have a much low-er viscosity and contain organic cations rather than inorganic ones. In thescientific community mostly a sub-set of the class of Ionic Liquids so

called Room-Temperature Ionic Liquids (RTILs) being salts with a meltingpoint lower than room temperature stand at focus. In order to achievesuch low melting points, cations or anions require an asymmetric chargedistribution and have to considerably differ in size. Both effects lower thecrystal lattice energy thus leading to a low melting point.This new class of substances offers a unique set of properties not achiev-able with any other material.Most notably, ILs exhibit virtually non-meas-urable vapor pressurescombinedwith a large temperature window for the

liquid phase. Additionally, they compriseexcellent thermal, mechanical and electro-chemical stability. These properties makethemsafe tohandleas theyare highly non-

New developmentsin pumps and compressors using Ionic Liquids

The class of new substances known as Ionic Liquids offers

outstanding combinations of properties not achievable with any other material, such asbeing liquid and showing literally no vapour pressure. Using

N e w sWORLDWIDE

A special edition from PROCESS 5

EBERHARD SCHLUECKER, LASZLO SZARVAS AND ERIC UERDINGEN

Prof. Dr.-Ing. E. Schluecker, institute of process machinery and plant technology, Friedrich-

Alexander-University Erlangen Nuremberg/Germany; Dr. L. Szarvas and Dr. E. Uerdingen, New

Business Development, Intermediates Division, BASF SE, Ludwigshafen/Germany

Picture:BASF

these liquidsas operating liquidsin pumps and compressors al-

lows remarkable improvementsby making additionally use oftheir good lubrication proper-ties, high temperature stabilityand low compressibility.

First focusing on applying them as al-ternative solvents in chemical process-es, Ionic Liquids are today discussed asnew materials in a broad range of ap-plications, e.g. as operating liquids inpump and compressor applications.


5/21

flammableaswellasusuallynon-explosive. Due to their outstand-ing physicochemical properties

ILshaverecentlyopenedthedoorto new applications.Room-temperature Ionic Liquidsusually consist of nitrogen-con-taining organic cations, the mostknown are N,N-dialkylimidazoli-um cations as described by: J. S.Wilkes, J. A. Levisky, R. A. Wilson,C. L. Hussey, Inorg. Chem. 1982,21, 1263; J. S. Wilkes and M. J.Zaworotko, Chem. Comm. 1992,965; and N-alkylpyridinium, F. H.Hurley, T. P. Wier, J. Elettrochem.

Soc. 1951, 98, 203; H. L. Chum,V. R. Koch, L. L. Miller, R. A. Os-teryoung, J. Am. Chem. Soc.,1975, 97, 3264; and commonweakly coordinating inorganicanions (AlCl

4, BF

4, CF

3SO

3, etc.)

(Figure 1).The chance to combine differentorganic cations with both inor-ganicandorganicanionsgivesanexceptional diversity on physicaland chemical properties of thesecompounds. Physical propertiessuch as solubility of gases can be

designedinthiswayaswellaslu-brication properties,temperaturestability and compressibility.Over the past few decades thenumber of publications concern-ing Ionic Liquids has increasedsubstantially, showing the con-tinuously growing interest inmany different research fields.First focusing on applying themas alternative solvents in chemical processes, they are today discussed asnew materials in a broad range of applications. In the following we willfocus on their utilization as operating liquids in pump and compressor ap-

plications.

Outstanding properties of ILs in pump andcompressor applicationsOffering the unique combination of being liquid and literally showing novapour pressure, ILs open new opportunities for operating liquids in pumpand compressor applications as they additionally can offer good lubrica-tion properties, high temperaturestability, low compressibilityand low sol-ubility for gases.The experimental search through many IL-types revealed also some ILswith better friction and wear values than normal motor oil (10 W 40) evenwithout additives. In combination with or without additives this opens abig chance for smaller mechanical losses in machines. Criteria for good lu-brication include an optimal viscosity and a small wetting ability angle,

which can be designed with the chemical structure.ILs are often non-corrosive, but esp. together with friction, corrosion ef-fects with ILs have been observed e.g. ILs with alkylsulfates as anion canbe hydrolyzed in the presence of water and can show severe corrosion ef-fects on e.g. ferrite steel. Therefore it is strongly recommended to check

the corrosivity of ILs to all mate-rials involved and under relevantconditions in the respective envi-

ronment.Beside other positive factors ILsoffer low compressibility. For ex-ample 1-ethyl-3-methylimid-azolium ethylsulfate (EMIMEtSO

4) shows 1/3 of the com-

pressibility of mineral oil and 2/3of water. Due to this, ILs enableremarkable improvements in theefficiencyof high pressure gener-ating pumps and pulsators (forfatigue testing) [2, 3].Remarkable positive effects can

be generated by the very smallvapour pressure of ILs togetherwith low gas solubility. Theseproperties predestine ILs for theuse as lubricating liquids in com-pressors and also vacuum pumps[2, 5].Already EMIM EtSO

4deliv-

ersgood results(see. ff)in this re-spect. The only disadvantage isthat EMIM EtSO

4has low tem-

perature stability (about 200C).This leads to the last and mostchallenging aspect. If ILs with ahigh chemical and also tempera-

tureresistance canbe developed,the direct contact with criticalchemicals or highly reactivegases would be possible. ILsthenmight be used for a liquid pistonorlubricationandinterfaceliquidin high temperature compres-sion. The chance for realizingsuch applications is quite good.

Application examples for pumps andcompressorsDue to the good lubrication capabilities of Ionic Liquids, often combined

with chemical inertia and stability, all machines using lubrication oil canexpect an improvement in efficiency. Preliminary tests with simple driveunits have already confirmed this expectation even without additives, andthe necessary long life requirements seem also to be fulfilled. With theseresults also the basic requirements for using IL in pumps and compressorsare given.The first idea for using ILs in pumps was to replace the hydraulic oil in hy-draulically driven diaphragm pumps with an Ionic Liquid with low com-pressibility. In suchmachinesthe compressibilityis linked withthe so calledvolumetric efficiency. Just by using EMIM EtSO

4instead of mineral oil, a

remarkable increase of the volumetric efficiency of about 10 to 30% wasachieved.The higher the pressure, the bigger the detrimental space (liquidcontent) or thesmallerthe adjusted stroke length,the biggeris thisbenefit.Furthermore, it can be expected that an Ionic Liquid can be found which

is able to decrease the gas dissolution effect during the suction process,so leading to a higher metering precision [2].The low compressibility effect is also beneficial in pressure pulsating de-vices for fatigue behaviour testing e.g. of common rail tubes. In this ap-plication, Ionic Liquids can nearly double either the number of parts test-

N e w sWORLDWIDE

6 A special edition from PROCESS

Figure 2: Characteristic delivery curves of liquid ring pumps with water andEMIM-EtSO

4

Figure 1: Common cations and anions for Ionic Liquids


6/21

ed with one machine or the volume of the parts [4], so introducing aneconomy of about 100% in the testing procedure.A liquid ring vacuum pump uses a star shaped impeller rotating eccen-

trically in a circular housing. The liquid ring is generated by this rotationand generates together with the impeller a positive displacement effectin each chamber of the impeller. The limit of the vacuum possible withthis machine is given by the vapour pressure and some design aspects.Just by replacing water with Ionic Liquid, the vacuum pressure was re-duced from about 70 mbar to about 10 mbar (Fig.2).Someimprovementsin the machine design allowed a further reduction to 1 mbar and evenlower pressuresappear to be achievable.This result, which is nearlyreadyfor introduction intothe market,offers a new field of applications for thistype of machine.Given adequate temperature stability, gas conveying processes can alsobe improved. An already available type is an Ionic Liquid piston com-pressor [2, 6] which acts like a reciprocating positive displacement com-

pressor,usually witha smaller stroke frequency.Thisdevice is already usedfor pure hydrogen and other gases. Because liquid can penetrate com-plicate working chambers or the piston can move along pipelines andaround bends, the volumetric efficiency (delivery rate) can be quite high,and with IL contact the compression process is close to isothermal.Using ILs with high temperature stability [3] higher compression ratiosand higher end temperatures are possible, and the danger of oil confla-gration does not exist anymore. From this result it is only a short step tothe use of high temperature stable Ionic Liquids as lubrication liquids inall types of positive displacement compressors [2], also with higher pres-sure ratios.Finally, two ILs were found which are able to withstand pure oxygen in a30 MPa pressure impact test several times and also in an aerosol state.Using this outstanding property, a lubricated oxygen compressor is pos-

sibly no longer a dream.

Summary and outlookThe brief examples described above prove, that the outstanding proper-ties of Ionic Liquids offer a lot of chances for remarkable improvementsin the pump and compressor technology. The efficiency of all lubricatedmachines, e.g. engines, can rise remarkably. An increase of up to 30%higher volumetric efficiency of high pressure pumps is achievable; theeconomics of pulsating pressure testing devices can be improved by upto 100%. Utilizing Ionic Liquids in liquid ring vacuum pumps can lowerthe vacuum pressure from about 70 mbar to below 1 mbar. Liquid pis-tons for gas conveying are already realised as well as higher pressureratios, due to the lack in danger of oil conflagration. Further, the realisa-

tion of the dream of lubricated oxygen compression is close to becomereality.Since Ionic Liquids can be tailored in order to optimize their properties,the authors firmly believe that in the future ILs will be designed, that areable to improve nearly each of the applications mentioned in this articleeven further. The authors are also convinced that this is not yet the end.There still is a wide open field for new ideas and applications.

N e w sWORLDWIDE


Literature[1] Wasserscheid, P.; Welton, T. (Hrsg.): Ionic Liquids in Synthesis, ISBN-10: 3-527-31239-0, ISBN-13: 978-3-527-31239-9; Wiley-VCH,Weinheim, 2007[2] Hilgers C. et. al., PCT Int. Appl. Processing or working machine comprising anionic liquid as the service fluid 2006, Chem. Abstr. 2006, 20060824.[3] Predel,T.; Schluecker, et.al: Ionic Liquids as Operating Fluids in HighPressureAp-plications, Chemical Engineering Technology, Volume 30 No.11, November 2007[4] Schluecker, E.: Verfahren zur Hochdruckpulsationsprfung von maschinellenBauteilen, PCT/EP2008/000118[5] Mller, C.et al.BASF (WO/2006/029884)Methodfor operating a liquid ringcom-pressor.[6] N.N.: LindeAnnual Report 2006


7/21

NNanofiltration based on polymer membranes is widely acceptedas a sep-aration technology for the treatment of aqueous streams. Now nanofil-

tration is on the threshold of being applied to separation tasks involv-ing organic solvents as well. Membrane separation in non-aqueous sys-tems, often called organophilic nanofiltration, can significantly reduceprocess costs, but requires different membranes and a profound knowl-edge of the behaviour of organic liquids. Organophilic nanofiltrationmembranes can separate molecules in the molecular weight range3001000 g/mol either impurities or target molecules from organicsolvents.In using membrane technology to separate organic solutes from organicsolvents, we are just beginning to understand the fundamental transportand removal mechanisms involved. For instance, we need to take into ac-count the swelling properties of the membrane, which depend on the in-teractions between the membrane and the solvent/solute system underpossibly varying operating conditions.

Polymers with the chemical resistance needed to act as organophilicnanofiltration membranes include polyimides, polyamide-imides, poly-acrylonitriles (copolymer, crosslinking), silicones, polyphosphazenes,polyphenylene sulfide, polyetheretherketone, and polybenzimidazol.The rejection performance of a membrane for solutes of different molecu-lar weights can be assessed using various approaches, including dye re-tention and direct measurements using different test solutes. The interac-tions referred to above can make this a complex business, but a rule ofthumb for the performance of a typical silicone membrane is:MW 300500 g/mol: 5070% rejectionMW > 600 g/mol: 80%+ rejectionMW > 1000 g/mol: ~100% rejectionCompared to other organophilic nanofiltration membrane materials, sili-cone allows effective separation at higher fluxes.

Nanofiltration based on polymer mem-branes is widely used to treat aque-

ous streams, and now it is on thepoint of being applied to organ-icliquidsaswell.Organophilicnanofiltration can separatemolecules in the weight range3001000 g/mol from organ-ic solvents, often at much low-er costs than alternative tech-nologies.

N e w sWORLDWIDE


THOMAS BEESKOW AND BJRN HOTING

Dr. Thomas Beeskow; GMT Membrantechnik GmbH, Rheinfelden/Germany;

Dr. Bjrn Hoting, Borsig Membrane Technology GmbH, Gladbeck/Germany

Pictures:GMT

Spiral-woundmodulesprovide aneffectiveextensionof thestandardmembrane

module design to organic solvents.

Nanofiltrationcomes to organic solvents Industrial organophilic nanofiltration unit


8/21

Industrial applicationsOrganophilic nanofiltration membranes withthisgeneralrejection profile can helpto solveindustrial separation tasks such as: treating fuels and stabilizing chemical in-termediates in the petrochemical industry; recovering homogeneous catalysts, a tasknormally performed using thermal separa-tion; separating highly viscous hydrocarbonsfromhigher-valuelow-viscosityhydrocarbonsin the petrochemical industry; simplifying downstream processes, and/or

debottlenecking, by removing hazardous compounds from hydrocarbonsin the petrochemical industry; and general purification of organic solvents in different industries.The technical literature often claims that the main limitation in extendingmembrane processes to treat organic solvents is the lack of availability ofcommercial organophilic membranes.This has changed over the past fewyears, and commercial organophilic nanofiltration membranes are nowavailable.

Membranes available from GMT show excellent stabilityin hydrocarbons at 80C and 40 bar, with reliable high re-tention at exceptionally high permeability.Themembranesare also stable in aromatics, alkanes, alcohols, ethers andketones.Theycan be usedin bothspiral-woundand LF (en-velope-type) modules. They are the result of the combina-tion of excellent research by GKSS, with GMTs ability tooptimize manufacture on a commercial scale.GMTspiral-wound modulesprovidean effective extensionof the standard membrane module design to organic sol-vents. GMT LF (envelope-type) modules add the advan-tages of high specific permeate flux; optimization of fluxand pressure drop using a flexible compartment design;optimal flow over the hydraulic discs; and optimal chem-ical resistance thanks to their adhesive-free design.Success in the applications referred to above needs morethan just an excellent commercial membrane, however.

Companies need membrane processes that will operate reliably in an in-dustrial environment, and this in turn requires an equipment manufactur-er who understands membrane processes. GMT works closely with BorsigMembrane Technology GmbH (membrane process system supplier) andPolyAnGmbH (lab-scale feasibilitytesting) to provide industrial membraneprocesses from laboratory through to industrial production scale. Indus-trial units have already been commissioned for the industrial applicationsmentioned above.

N e w sWORLDWIDE

Envelope-type modules show optimal chemical

resistance thanks to their adhesive-free design.

M5-851-16-FA-243167.qxd 03.03.2008 9:25 Uhr Seite 9


9/21

TThe classification of dangerous chemicals in the EU is currently complete-ly under revision. As a result the Substances Directive (67/548/EEC) andthe Preparations Directive (1999/45/EC) are to be replaced by the GHS-Regulation. This Regulation will be the implementation of a recommen-dation of the United Nations (Globally Harmonized System of Classifica-tion and Labelling of Chemical, UN-GHS) into Community Law.The GHS defines physical, health and environmental hazards which aredivided into hazard classes reflecting the type of hazard (e.g.explosive, oracutely toxicor hazardousto the aquatic environment).These hazard class-es are further divided into categories which (in most cases) reflect the de-gree of hazard. The criteria for the hazard classes and categories are laid

down in Annex I of the GHS-Regulation.Each hazard category has specific label elements assigned consisting of apictogram, a signal word (either Danger or Warning), a hazard state-

ment and precautionary statements (see table below for an example).Thehazard statements are the GHS-equivalent of the currently used R-phras-es according to the Substances Directive and the precautionary statementsare the GHS-equivalent of the currently used S-phrases.The European GHS-Regulationwill implementall hazardclassesof theUN-GHS but not all categories. For this the GHS-Regulation makes use of theso-called Building Block Approach of the UN-GHS which allows to imple-menting only parts of the UN-GHS under certain conditions.The EU main-ly uses this tool in order to stay as close as possible to the current systemof classification of dangerous chemicals.

Changes in classification Physical hazards: The physical hazard classes are structured differentlythan in the current EU-System. Even so, the new system is not an unfa-miliar system. The GHS is based on the classification system which is al-ready applied for the Transport of Dangerous Goods. The result is a verydifferent system for the classification of explosives. Moreover, some haz-ard classes in the transport system are not part of the current system in

the Substances Directive and therefore are newly in-troduced. Examples are: gases under pressure, self-re-active substances, self-heating substances.However, most of the substances assigned to thesehazard classes have been classified as dangerous be-fore (e.g. as explosive or flammable). Exceptionsare in-

ert gases under pressure. Health hazards:As a first approximation, the healthhazard classes and also the classification criteria arerather similar in the GHSand the Substances Directive.The main change under the GHS is a change in the cat-egory criteria (cut-off values) in the classification foracute toxicity.About one per cent of the hazardoussubstances mightchange their acute toxicity classification into a morestringent one.Also with respect to the classification ofaspiration hazards, the criteria are more stringent. Forfurther health hazards, the change in the criteria forsubstance classification is minor. The classification ofmixtures will be different as the concentration limits

for classification of skin/eye corrosives/irritants arelower leading to more mixtures being classified withthe GHS.However, the margin of evaluation with the new sys-tem isbroader asit isallowed to deviatefromthe stan-

New GHS-Regulation

Implementation of the GHS (GloballyHarmonized System) in the EU Whatare the changes?

N e w sWORLDWIDE


JULIANE KOCH, CORDULA WILRICH, THOMAS GEBEL

Dr. Juliane Koch, Umweltbundesamt, Dessau/Germany; Dr. Cordula Wilrich, Bundesanstalt

fr Materialforschung und -prfung BAM, Berlin/Germany; Prof. Dr. Thomas Gebel, Bundes-

anstalt fr Arbeitsschutz undArbeitsmedizin, Dortmund/Germany

Classification Category 1 Category 2 Category 3

GHS Pictograms

Signal word Danger Danger Warning

Hazard statement H224:Extremely flammable liquid

and vapour

H225:Highly flammable liquid

and vapour

H226:Flammable liquid

and vapour

PrecautionaryStatementPrevention

P210P233P240P241P242P243P280

P210P233P240P241P242P243P280

P210P233P240P241P242P243P280

Precautionary

Statement Response

P303 + P361 + P353

P370 + P378

P303 + P361 + P353

P370 + P378

P303 + P361 + P353

P370 + P378

PrecautionaryStatement Storage

P403 + P235 P403 + P235 P403 + P235

PrecautionaryStatement Disposal

P501 P501 P501

Label elements assigned to the hazard class flammable liquids


10/21

dard criteria in case an evaluation using expert judgment leads to a dif-ferent classification.Environmental hazards:Classification of environmental hazards is based

on acute and chronic hazards to the aquatic environment. On contrary tothe Substances Directive, GHS clearly separates acute and chronic aquat-ic hazards. For acute aquatic hazards not all categories of the UN-GHS willbe included into the GHS-Regulation. In addition, the GHS offers the op-tion to usean additivity formula to classify thehazard to waters which wasnot possible with the Dangerous Preparations Directive.As a so-called EU-left-over the GHS-Regulation will contain classificationcriteria and labelling elements for ozone depleting chemicals.GHS as a living document allowsfurther development and processat UN- and OECD-level. In relationtoenvironmentalhazardstheworkon the development of classifica-

tion criteria and labelling provi-sions continues for terrestrial haz-ards and for ozone depletion. Thelatter is just about to be amended.Once further criteria have beenagreed on the international levelthey then can be implemented inthe EU.

Harmonizedclassification andlabelling of substancesThe GHS-Regulation will contain alistofharmonizedclassificationsof

substances in Annex VI. The sub-stances in this list are those thatare currently contained in the cor-responding list of the SubstancesDirective but with transferred clas-sifications according to the GHS.Further substances may be includ-ed into this list if they are of highconcern (classification for respira-tory sensitisation, germ cell muta-genicity,carcinogenicity,reproduc-tive toxicity).Other substances canbe included on a case-by-case ba-

sis provided that the need for suchaction at Community level can bejustified.

Classification andlabelling inventoryThe Classification and Labelling In-ventory is a further instrumentwhich aimsat consistent classifica-tion within the EU. Any classifica-tion within the EU has to be noti-fied to the new European Chemi-calsAgency (ECHA) which publish-estheseclassifications.Atthesame

time the Agency has to inform allnotifiersincasetheirclassificationsdiffer from eachother.The notifiersthen are supposed to agree on aconsistent classification.

The transitional periods are phased for substances and mixtures.Substances have to be labelled according to the GHS-Regulation fromDecember 1st, 2010 on and mixtures from June 1st, 2015 on. Before the

end of these transitional periods labelling may already be done accordingto the GHS-Regulation.During the transitional periods the SafetyData Sheet must also contain in-formation aboutthe classificationaccording to the current Substances andPreparations Directive so that downstream users are able to classify mix-tures which they manufacture according to the old system if they havenot yet changed to the GHS.After June 1st, 2015 the Substances and thePreparations Directive are supposed to be revoked.

N e w sWORLDWIDE



11/21

TThe classification of dangerous chemicals in the EU is currently complete-ly under revision. As a result the Substances Directive (67/548/EEC) andthe Preparations Directive (1999/45/EC) are to be replaced by the GHS-Regulation. This Regulation will be the implementation of a recommen-dation of the United Nations (Globally Harmonized System of Classifica-tion and Labelling of Chemical, UN-GHS) into Community Law.The GHS defines physical, health and environmental hazards which aredivided into hazard classes reflecting the type of hazard (e.g.explosive, oracutely toxicor hazardousto the aquatic environment).These hazard class-es are further divided into categories which (in most cases) reflect the de-gree of hazard. The criteria for the hazard classes and categories are laid

down in Annex I of the GHS-Regulation.Each hazard category has specific label elements assigned consisting of apictogram, a signal word (either Danger or Warning), a hazard state-

ment and precautionary statements (see table below for an example).Thehazard statements are the GHS-equivalent of the currently used R-phras-es according to the Substances Directive and the precautionary statementsare the GHS-equivalent of the currently used S-phrases.The European GHS-Regulationwill implementall hazardclassesof theUN-GHS but not all categories. For this the GHS-Regulation makes use of theso-called Building Block Approach of the UN-GHS which allows to imple-menting only parts of the UN-GHS under certain conditions.The EU main-ly uses this tool in order to stay as close as possible to the current systemof classification of dangerous chemicals.

Changes in classification Physical hazards: The physical hazard classes are structured differentlythan in the current EU-System. Even so, the new system is not an unfa-miliar system. The GHS is based on the classification system which is al-ready applied for the Transport of Dangerous Goods. The result is a verydifferent system for the classification of explosives. Moreover, some haz-ard classes in the transport system are not part of the current system in

the Substances Directive and therefore are newly in-troduced. Examples are: gases under pressure, self-re-active substances, self-heating substances.However, most of the substances assigned to thesehazard classes have been classified as dangerous be-fore (e.g. as explosive or flammable). Exceptionsare in-

ert gases under pressure. Health hazards:As a first approximation, the healthhazard classes and also the classification criteria arerather similar in the GHSand the Substances Directive.The main change under the GHS is a change in the cat-egory criteria (cut-off values) in the classification foracute toxicity.About one per cent of the hazardoussubstances mightchange their acute toxicity classification into a morestringent one.Also with respect to the classification ofaspiration hazards, the criteria are more stringent. Forfurther health hazards, the change in the criteria forsubstance classification is minor. The classification ofmixtures will be different as the concentration limits

for classification of skin/eye corrosives/irritants arelower leading to more mixtures being classified withthe GHS.However, the margin of evaluation with the new sys-tem isbroader asit isallowed to deviatefromthe stan-

New GHS-Regulation

Implementation of the GHS (GloballyHarmonized System) in the EU Whatare the changes?

N e w sWORLDWIDE


JULIANE KOCH, CORDULA WILRICH, THOMAS GEBEL

Dr. Juliane Koch, Umweltbundesamt, Dessau/Germany; Dr. Cordula Wilrich, Bundesanstalt

fr Materialforschung und -prfung BAM, Berlin/Germany; Prof. Dr. Thomas Gebel, Bundes-

anstalt fr Arbeitsschutz undArbeitsmedizin, Dortmund/Germany

Classification Category 1 Category 2 Category 3

GHS Pictograms

Signal word Danger Danger Warning

Hazard statement H224:Extremely flammable liquid

and vapour

H225:Highly flammable liquid

and vapour

H226:Flammable liquid

and vapour

PrecautionaryStatementPrevention

P210P233P240P241P242P243P280

P210P233P240P241P242P243P280

P210P233P240P241P242P243P280

Precautionary

Statement Response

P303 + P361 + P353

P370 + P378

P303 + P361 + P353

P370 + P378

P303 + P361 + P353

P370 + P378

PrecautionaryStatement Storage

P403 + P235 P403 + P235 P403 + P235

PrecautionaryStatement Disposal

P501 P501 P501

Label elements assigned to the hazard class flammable liquids


12/21

dard criteria in case an evaluation using expert judgment leads to a dif-ferent classification.Environmental hazards:Classification of environmental hazards is based

on acute and chronic hazards to the aquatic environment. On contrary tothe Substances Directive, GHS clearly separates acute and chronic aquat-ic hazards. For acute aquatic hazards not all categories of the UN-GHS willbe included into the GHS-Regulation. In addition, the GHS offers the op-tion to usean additivity formula to classify thehazard to waters which wasnot possible with the Dangerous Preparations Directive.As a so-called EU-left-over the GHS-Regulation will contain classificationcriteria and labelling elements for ozone depleting chemicals.GHS as a living document allowsfurther development and processat UN- and OECD-level. In relationtoenvironmentalhazardstheworkon the development of classifica-

tion criteria and labelling provi-sions continues for terrestrial haz-ards and for ozone depletion. Thelatter is just about to be amended.Once further criteria have beenagreed on the international levelthey then can be implemented inthe EU.

Harmonizedclassification andlabelling of substancesThe GHS-Regulation will contain alistofharmonizedclassificationsof

substances in Annex VI. The sub-stances in this list are those thatare currently contained in the cor-responding list of the SubstancesDirective but with transferred clas-sifications according to the GHS.Further substances may be includ-ed into this list if they are of highconcern (classification for respira-tory sensitisation, germ cell muta-genicity,carcinogenicity,reproduc-tive toxicity).Other substances canbe included on a case-by-case ba-

sis provided that the need for suchaction at Community level can bejustified.

Classification andlabelling inventoryThe Classification and Labelling In-ventory is a further instrumentwhich aimsat consistent classifica-tion within the EU. Any classifica-tion within the EU has to be noti-fied to the new European Chemi-calsAgency (ECHA) which publish-estheseclassifications.Atthesame

time the Agency has to inform allnotifiersincasetheirclassificationsdiffer from eachother.The notifiersthen are supposed to agree on aconsistent classification.

The transitional periods are phased for substances and mixtures.Substances have to be labelled according to the GHS-Regulation fromDecember 1st, 2010 on and mixtures from June 1st, 2015 on. Before the

end of these transitional periods labelling may already be done accordingto the GHS-Regulation.During the transitional periods the SafetyData Sheet must also contain in-formation aboutthe classificationaccording to the current Substances andPreparations Directive so that downstream users are able to classify mix-tures which they manufacture according to the old system if they havenot yet changed to the GHS.After June 1st, 2015 the Substances and thePreparations Directive are supposed to be revoked.

N e w sWORLDWIDE



13/21

SSince 1995, Indiastotal pharma industry R&Dspendinghasrisen from around USD 30 million to more than USD 495.2million in 2005. The vast majority of the national pharmaindustrys R&D expenditures on newdrug discoveryand de-velopment is conducted by a limited number of companies,e.g. Dr. Reddys (2005: 14% of annual sales) and Ranbaxy

(2005: 7%).Indias biotech sector is among the fastest growing knowl-edge based sectors, growing from USD 800 million in 2003to USD 1.45 billion in 2005, and reaching USD 2 billion in2006. Over the past few years, the biotech industry has in-vested around 25% of its revenues with a high proportionof the investments going into the setting up of infrastruc-tures, followed by R&D.

Indias growing contract researchmarketIn 2005, global outsourcing expenditure amounted to USD34 billion of which 60% was spent on contract manufac-

turing, 33% on clinical research and 7% on custom chem-ical synthesis.Indias contract research and manufacturing market grewfrom USD 0.5 billion in 2005 to USD 0.9 billion in 2006 andhas been contributing close to 8% to the total Indian phar-maceuticalbusiness over the last five years. Experts believeit will reach USD2.7 billion by 2010 with Indian companieshaving the capacity to gain between 35% and 40% of theglobal contract research and manufacturing market.From an estimated USD 75 million in manufacturing con-tracts in 2004, the Associated Chambers of Commerce andIndustry of India (ASSOCHAM) expects the contract manu-facturing market to reach USD 900 million by 2010. IndiasAPI manufacturing industry is already the third largest in

the world with sales of USD 2 billion in 2005 and expect-ed to reach USD 4.8 billion by 2010 with an average an-nual growth rate of 19.3%.

For pharma contract research, India has become one of the preferred out-sourcing destinations as reflected in its annual growth rate of 2025%.Clinical trials make up 65% of all pharma contract research business with

the remaining 35% in the field of new drug discovery. According to Busi-ness Insights, clinical trails conducted in India are to grow from 1.5% ofglobal clinical trials in 2006 to 5% by 2008 and 15% by 2011. Indian con-tract research organisations offering small-scale discovery and develop-ment services generally also have the capacity to take on limited formu-lation and manufacturing scale-up activities.In the custom synthesis market, with the shift from generic to innovativedrug discovery, an annual growth rate of 2025% is expected for innova-tor companies while a growth rate of 1015% is expected in the genericindustry. Services in synthesis, drug design, analytical and medicinal chem-istry, and assay development are being offered by an increasing numberof Indianvendors,such asMithros Chemicals,and a numberof major multi-national companies, such as Abbott, Bayer, Glaxo Smith-Kline and Merck,

are already outsourcing various chemical synthesis projects to Indianservice providers.With the growing demand for outsourcingservices, Indian companieshavemade acquisitions in the contract research and manufacturing sector, inorder to scale up rapidly and have adequate infrastructure in place.Typesof acquisitions include manufacturing facilities in China to access low costAPIs; contract research organisations in Europe to leverage on existing

Pharmaceuticalandbiotechnologycompaniesareincreasinglyoutsourcingearly-stageresearchand

clinical studies driven mainly by rising R&D costsand the need to improve R&D productivity. Withcost savings of around 3050% compared to

Western costsas well as anabundanceoftalented sci-

entists and easy access to raw materials, India isseen as a key location for outsourcing researchand manufacturing in the area of drug discovery

and development.

N e w sWORLDWIDE


GUNTER FESTEL

Gunter Festel, Festel Capital, Hnenberg/Switzerland

97.8

130.5

(Change

33%)

175.3

(34%)

208.0

(60%)

392.4(40%)

495.2

(26%)

0

100

200

300

400

500

Value(USDmillion)

2000 2001 2002 2003 2004 2005

137,2

183,6

276

366

0

100

200

300

400

USDmillion

2003 2004 2005 2006

Indias pharma R&D expenditures from 2000 to 2005

Source:AssociatedChambersofCommerceand

IndustryofIndia

Biotech investment track from 2003 to 2006

Source:IMaCSConsulting

Lets go to India


14/21

client relationships of acquired companies; ac-quisitions to bride the gaps in the service offer-ingsandbecomefullserviceplayers;acquisitionsto gain accessto newer technology platformsforhigh-end custom synthesis and clinical researchwork and new clients.

India as attractive outsourcinglocationMajor international companies have identifiedIndia as a key location for various drug discov-

ery and development projects, such as customsynthesis.With a largepool of talented scientists especially in synthetic chemistry at R&D per-sonnel costs around a third of those in Europe,availability of low cost, high quality production,easy access to rawmaterials andfaster approvalof drugs than those produced in Western coun-tries, multinational pharma and biotech compa-nies canachieve cost savings of around3050%when outsourcing projects to India.Pharmaoutsourcing rangesfroma onetimesup-ply to a partnering agreement,whereby, accord-ing to a market study conducted by Festel Capi-

tal and Taros Chemicals on outsourcing chemi-cal synthesis to India, the trend is towards longterm relationships between the Indian pharmacompanies and the multinational companiesleading to a preferred vendor status for the In-dian companies. Multinational companies, suchas Abbott, AstraZeneca, Eli Lilly, GlaxoSmith-

Kline, Merck, Novartis, Pfizer and Solvay, are allusing the services of contract research organi-sations.There are various key attributes for Westernpharma companies when looking for an Indianpartner, such as, effective and rapid decisionmaking, the ability to solve day to day as well asstrategic issues, and understanding and appre-ciation of business norms in Europe and US.One of the main concerns of multinational com-panies when considering outsourcing to India is

inefficient intellectual property (IP) protection.Many are concerned about threats to IP and therisk of losing IP rights. In recent years, Indiaspatent act and rules have been amended signif-icantly in view of the Indian Governments in-ternational commitment under the TRIPS (inter-national agreement on trade-related aspects ofintellectual property rights) agreement,and withits last amendment in 2005, the patent act con-forms to the TRIPS agreement, including thegrant of product patents. Alternative statutoryprotection in India, especially for sensitive R&Ddata and know-how from the discovery phase,

is provided by Indias Contract Act and relatedlaws that correspond to those of similar statutesin the UK. In recent years, the government hasalso introduced policies, such as stringent regu-lations,mandatory good manufacturing practice(GMP)compliance and improved legislations forclinical trials.

N e w sWORLDWIDE

Concerns of customers Approach of service providers

Complexity and efficiencyDefinition of highly standardised andtransparent processes and contracts

Intellectual property (IP)Co-operation agreement leaving allcritical IP at the customer

Exclusivity and secrecyClear and transparent rules regarding theengagement in projects of directcompetitors

Costs and invoicingEstablishing full cost transparency andeasy invoicing process

1

6

5

3

Co-operation and communicationProject management in close vicinity tothe customer (e.g. in Europe) and notonly lab resources in India

2

Flexibility and qualityHigh flexibility regarding project executionwith stringent quality control

4

Indian company Asset acquired Year

Dishman Pharmaceuticals and Chemicals SynprotecCarbogen and AmicsSolvays cholesterol, vitamin D and analogs business

200520062007

Jubilant Organosys Trinity Laboratories

Hollister-Stier

2005

2007

Nicholas Piramal Avecia PharmaBio SyntechPfizers Morpeth UK-based manufacturing business

200520052006

Shasun 2 UK-based Rhodia plants 2006

Approach of service providers to the concerns of customers

Source:FestelCapitalanalysis

Examples of acquisitions made by Indian companies


15/21

I

In Singapore, the idea for an integrated chemicals hub was mooted in the1980s, when it became evident that the chemical cluster was capable ofcontributing significantly to the economic growth of Singapore. Singaporeis currentlythe leading oil trading hub inAsia (third in theworldafterNewYork and London) and the worlds third-largest oil refining center behind

Houston and Rotterdam.The chemicals cluster in Singapore includes the petroleum, petrochemicalsandspecialtychemicalsindustries,withfirmsinvolvedinrolesrangingfrommanufacturing, logistics and trading to services like power generation.To-day, Singapore ranks amongst the top three global centers for oil refining,oil trading, and price discovery. It is also one of the worlds top ten petro-chemicals hubs.The Jurong Island, a sporadic collection of seven islets into an integratedislandwithanareatotalofabout32km 2, is a well-integrated modern com-plex; a world-class chemicals hub in the region. Today, Jurong Island ishome to over 88 leading petroleum, petrochemical,specialty chemical andsupporting companies with more than S$24billion in fixed assets invest-ment on Jurong Island. Industry luminaries such as ExxonMobil and Shell

havealreadyestablishedastrongpresenceonJurongIslandandarepoisedto reap the benefits of comprehensive infrastructure and production syn-ergies from this unique cluster development.

Well-established infrastructureThere is a strong reason for the impressive portfolio of companiesthat are currently on Jurong Island. It is the well-established infra-structure on the island. Companies on Jurong Island are verticallyintegrated and interlinked by the common pipeline service corridorto create synergy and efficiency. Feedstock and products are sup-plied anddispatchedfromplantto plant viathenetwork ofpipelines,as the output of one plant is the input of another as a result of thecluster manufacturing arrangement. On top of plant to plant syn-ergy, companies on the island reap economies of scale, enjoy in-

creased operational efficiency and cost savings. All these are thebenefits of the minimal requirement for storage facilities and long-haul distribution brought about by the intelligent infrastructure.

AsthechemicalhubofSoutheastAsia,Singaporeschemicalsindustryover-took the electronics sector to become the top contributor to manufactur-ing output in 2006. The clusters 2006 output reached S$74.7 billion, or33 per cent of total manufacturing output. The pharmaceuticals industryalso did exceptionally well in 2006 contributing to 91 per cent of the

total output by the Biomedical Sciences (BMS) industry, which reachedS$23 billion, according to figures released by the Singapore Economic De-velopment Board (EDB). This translated into S$20.93 billion in pharma-ceutical output, a 32 per cent rise.In addition to thegrowing scenario in thechemicals cluster, Singaporewillbe an excellent potential as a center for Asian biofuel production, with acentral location in terms of product and feedstock flows. The Finland re-finer Neste Oil will be building a palm oil-based biodiesel plant in Singa-pore due in 2010.Elsewhere in the ASEAN region especially in Malaysia, Thailand, Vietnamand Indonesia, the chemical industry is also enjoying strong growth withlarge number of projects coming on stream.This buoyancy has translatedinto opportunities and challenges for the regional process industry, which

is expected to boom through 2010. To effectively capitalize on the manybusiness opportunities, industry players are exploring innovative solutionsto take advantage of the surge in demand.

Riding high on increasing demandsin the region, the Association ofProcessIndustry (ASPRI) represent-ing the supporting industry for thechemicalssector,hastakentheleadto initiate an internationalplatformfor players of the process industryto network, update and upgrade.Developed by the industry for theindustry, ProcessCEM Asia 2008,theInternationalExhibition & Con-

ference on Plant Construction, En-gineering & Maintenance for theProcess Industry will be held in Sin-gapore at Suntec Singapore from22 to 24 October 2008.

Singapores chemicals industryon the fast track

As the chemical hub of Southeast Asia, Singapores chemicals industry overtookthe electronics sector to become the top contributor to manufacturing output.

N e w sWORLDWIDE


Peter Lee, Manager Industry Development, ASPRI Secretariat, Singapore

PETER LEE

ProcessCEM Asia 2008 is a multi-facetedplatform that features showcase, experi-ence and expertise sharing, site visits aswell as networking opportunities for theinternational process industry.

For more information, please log on to theweb site at: www.processcemasia.com

or contact ASPRI:(Association of Process Industry):Phone: +65-65604885e-mail: [email protected]

or MP Asia/Pico Event ManagementPhone: +65-63930237e-mail: [email protected]

ProcessCem Asia 2008

The Jurong Island, a sporadic collection of seven islets into an in-

tegrated island with an area total of about 32 km2, is a well-inte-

gratedmoderncomplex;aworld-classchemicalshubintheregion.


16/21

N e w sWORLDWIDE


Picture:Grundfos

Energy efficiency at thePump Users InternationalForum 2008The Pump Users International Forum, organ-ized by theVDMAs Pumps + Systems Associ-ation, takes place on October 28/29, 2008 inthe Dsseldorf Congress Center. It will offer

an unrivaled platform, especially for plant en-gineers and users of pumps and pump sys-tems, to learn about all the latest develop-ments in this area.

with modest investment andrapid paybacks. But getting the

message across requires a pro-fessional approach thatdoes notappear to push particular prod-ucts or manufacturers, a recentlarge study in Germany found.

Energy saving will increasingly make

use of intelligent components:learningsystems thatareable to adjustto external requirements by them-selves. Pumps and pump systems, forexample, can be instrumented andlinked by a fieldbus to a central moni-toring station, allowing them to beself-servicing. The picture showsbus-enabled Grundfos CR series high-pressure centrifugal pumps in use.


17/21

such as systems analysis and sustainability alsofeatured.

Convincing figuresThe launch year of 2004 was not an ideal timeto be selling energy saving; energy prices hadnot yet really begun to soar, and the unexpect-edly powerful resurgence in the German econo-my was yet to materialize.As a result, initial re-sponses to the campaign were lukewarm.However, pump users persuaded to take part in

a first consultation soon started to give positivefeedback. Calculations confirmedwhat the part-

nercompanieshadalwaysknown:savingscouldbe made, at expected levels, in virtually every in-dustrial sector. And as expected,each of the tenanalyses in the more extensive second consul-tation stage revealed even higher savings po-tential.

A big advantage of the campaign lay in its neu-tral presentation.While the consultants were allprovided by the partner firms, they operated asrepresentatives of the VDMA/dena campaign.As such, and because the recommended meas-

N e w sWORLDWIDE


Exemplary allocation ofcosts over the life cycle ofwater-bearing pumpsystems

Source:dena,

VDMA

Pumping partnersThe campaign Energy Efficient Systems in In-

dustry and Production was set up and carriedout by Deutsche Energie-Agentur GmbH (dena;the German Energy Agency) and the Pumps +Systems Association of the VDMA (German En-gineering Federation), and sponsored by theFederal Ministry of Economics and Technology.The industrial partners were AGO AG Energie +Anlagen, Danfoss GmbH, the German CopperInstitute DKI, Grundfos GmbH, KSB AG, SulzerPumpen GmbH and Wilo AG.The campaign focused on improving the energyefficiency of pump systems, along similar linesto that of the European Unions Motor Chal-

82%

10%

8%

Energy costs (capitalized over 10 years)

Maintenance and other costs (capitalized over 10 years)

Acquisition costs

lenge Program (MCP) for energy savings in the

field of motor driven systems. It was part of theEnergie Effizienz (Energy Efficiency) initiative forthe efficient use of electricity. This is supportedbydenaand theenergy companiesE.ONEnergieAG, EnBW AG, RWE Energy AG and VattenfallEurope AG, and sponsored by the Federal Min-istry of Economics and Technology.

Contact:Friedrich KltschVDMA e.V., FV Pumpen + SystemePhone: +49 (0)69-6603-1286E-mail: [email protected]

ures were not tied to specific products, they metsignificantly less resistance on the part of theusers.Even so, approval for implementing the pro-posedmeasuresonlyreally came when theshortpayback times of the measures were clearlyspotlighted.

Pumping trendsEnergy saving will increasingly make use of in-telligent components: learning systems that

are able to adjust to external requirements bythemselves. Pumps and pump systems, for ex-

ample,canbeinstrumentedandlinkedbyafield-bus to a central monitoring station, allowingthem to be self-servicing.In the case of mass-produced pumps, the trendwill be increasingly towards lowerperformance,countering the past tendency to provide operat-

ing margins that are more generous than nec-essary. To ensure that pumps match their oper-ating conditions, manufacturers competence inpump systems will become increasingly impor-tant.


18/21

TThe UK is a global centre of Life Science creativity and in investment terms,the UK leads in Europe and is second only to the USA.The pharmaceuticalindustry alone contributed over 12billion to UK exports in 2006.Many of the key tools of bioscience, such as genomics, proteomics, nano-technology, and bioinformatics, all address numerous medical challengesand have attracted significant investment from both smaller biotech com-panies and larger pharmaceuticalmanufacturers.The nations and the com-paniesthat will gain the most from the resulting bioscience revolution willbe thosethat implementthe best strategies to optimize thesuccessfulcon-vergence of these varied bioscience technologies.Developing global healthcare solutions is the prime motive force for themajority of bioscience companies. Drug development, diagnostic testing,biomarkers and new generations of medical devices and surgical implantsare all stimulatinghuge growth in biotechnology and pharmaceuticalmar-

kets.

Technology convergenceThere are a number of key technologies driving the bioscience industry.They include: genomics, proteomics, nanotechnology, bioinformatics andadvanced imaging techniques. Genomics: The sequencing of the genomes of viruses and bacteria isuseful tool in the fight against infection. Genomics the study of an or-ganisms entire genome is helping to predict the complex interplay ofgenes in a body. From that understanding come clues to potential ways totreat particular medical conditions as well as helping to create diagnostictests for specific illnesses.

Proteomics the study and comparison of the full protein complementof cells and their interactions, using large-scale methods for the simulta-neous analysis of many proteins. Proteomics research techniques such asPolymerase Chain Reaction (PCR),and RNA interfaceare enabling the ma-nipulation of genesin order to study their function or forindustrial or thera-peutic purposes. Advances in the ways biotechnologists can look at pro-teinsare helping thecorrelationof protein expression with statesof health.Using gene chip arrays researchers can determine which genes areswitched on at any moment and which proteins are being produced. Nanotechnology is increasingly being utilized in the development ofbiosensors, medical devices and drug delivery methods, and looks set toplay a vital role in many areas of healthcare that will drive further bio-science developments. Bioinformatics is also having a significant impact on the way bioscience

is being implemented and how the research community operates and in-

UK aims to optimizebioscience opportunitiesThe UK Government is currently gearing up to im-

plement a new marketing strategy for promotingthe UKs expertise in the biotechnology, pharma-ceutical and healthcare sectors. The new strategyaims to bring together Government and businesstogivetheUKsLifeSciencesectorstheloudestpos-sible voice on the world stage.

N e w sWORLDWIDE


MIKE DAY AND PAUL CARTER

Mike Day is ACHEMAs UK and Ireland representative and is responsible for helping to increase the number of international exhibitors signing up for ACHEMA 2009.

Paul Carter of Phoenix Marcom, a marketing communications company specialising in the science and industry sector, is supporting Mike Day in his task. Phoenix Marcom has a proven track

record with high tech companies, especially in the laboratory and analytical sector, which was the largest British exhibition group at ACHEMA. Pictures:U.S.

DepartmentofEnergyGenomePrograms(http://genomics.ener

gy.gov),

archives;[M]-Kansog


19/21

teracts. The research and development labora-toriesare increasingly relying on IT for data cap-ture, analysis, modelling and sharing. The in-creasing popularity of Laboratory InformationManagement Systems (LIMS) is a case in point.Bioscience often requires pooling the efforts oflarge, international research teams collaborat-ing and sharing knowledge and results data viaLIMS across wide area networks. Advanced imaging techniques particularlythose based on fluorescence are enabling re-searchers to see molecular reactions take place

in real time and in vivo.These advanced analyt-ical techniques enablescientists to study theim-pact of biopharmaceuticalson thebodyand pro-vide essential feedback to drug developers.

The UK bioscience perspectiveIn the UK the prime engine driving bioscience isthe industrys significant drug developmentpipeline.The UK has the largest biological med-icines development pipeline in Europe.There areabout30percentmoreproductsindevelopmentin the UK compared with its nearest Europeancompetitor.There are about 200 drug candidates currently

in development in the UK with about ten per-cent of them well advanced and now in PhaseIII clinical trials.TheUK biotechnology sub-sectorfeatures about400companiesandgeneratesrevenuesofabout5 billion. More than 25,000 people are em-ployed by UK biotechnology organizations. Themajority of bioscience employees are based atsmall,young and privatelyheld companies. If theUKs bioscience industry growth rates continuethe figures in terms of sales and employees arelikely to have tripled by 2015.The UK is ahead of its major European rivals in

Switzerland, France, and Germany.The UK posi-tion compared with its European rivals is alsostrengthened when you take into account thebioscience activities of major multinationalpharmaceutical companies. Although the UKpharmaceutical industry accounts for aboutthree per cent of world sales the country ac-counts for ten per cent of the worlds pharma-ceutical R&D expenditure.Biopharmaceuticals based on natural macro-molecules, such as human proteins, are begin-ning to make a substantial contribution to thehealthcare sector. Indeed, biopharmaceuticaldrugs account for about ten per cent of total

pharmaceuticalmarketsales,and are the fastestgrowing part of the market. They will be an in-creasingly important factor during the nextdecade. A third of all drugs currently in devel-opment are now biologics.

Key advantages of UKbioscienceThe UK bioscience sector has a number of com-

petitive advantages compared with itsother Eu-ropean rivals. One key advantage is the relativematurity of UK companiesin the bioscience sec-tor.In an industry that suffers from lengthy prod-uct development timescales, the UK already hasestablished a number of profitable public com-panies and a growing number of actively mar-keted products. Rival companies in Singapore,Ireland,India,andChinaarestillrelativelyyoungcompared to those in theUK.Another plus pointfor the UK is that it supports a strong bioscienceresearch base. More than 20 Nobel laureateshave been awarded for biomedical research at

UK research institutes during the past 40 years.There is also the major presence of several largepharmaceutical companies engaged in bio-scienceresearchandmanufacturingintheUKandthe unique influence of the NHS has the poten-tial to make undertaking clinical trials of thenewgeneration of biopharmaceuticals in the UK anattractive proposition for many drug developers.Many of these benefits have resulted in the UKbuilding a pool of experienced scientists, seniormanagers, investors, and serial entrepreneurswho have played roles in multiple companies.The UK Governments new Life Science market-ingstrategyis formulated to be a catalyst forthe

continued promotion of the UK Life Science sec-tors to a global audience. The new marketingstrategy includes: establishing a marketing strategy board bySpring2008thatismadeupofbusinessandgov-ernment leaders charged with implementing themarketing initiatives;developingasharedmarketingchartertohelpGovernment and business sell the UKs Life Sci-ence sectors consistently and persuasivelyaround the world to potential buyers and part-ners or potential inward investors; developing individual marketing campaigns

for each of the three sectors biotechnology,pharmaceuticals, and healthcare;working in partnership and pooling resourcesbetween business, trade associations, clusterand research organisations, universities andGovernment to sell the strengths of the UK asthe location of choice for inward investors.Leading the way forward is bioProcessUK,whichhas identified there are a number of UK univer-sities with strong academic capabilities in bio-processing researchcapable of deliveringskilledcandidates for the bioprocessing sector, whichcould be developed into Centres of Excellencethat will reinforce the UKs position as a global

hub of education in bioprocessing.The UK already has a strong reputation in cer-tain areas of bioprocessing, such as cell thera-pies and tissue engineering, and in formulationand drug delivery.

N e w sWORLDWIDE



20/21

HHaving finalized the first step inACHEMAs booking routine recently itis already now obvious that ACHEMA2009 will benefit from the current strongposition of the global chemicalindustry.Af-terseveral years of focussingon cutting costsin the process industries we now witness abroad trend to either invest in new plants or to up-grade existing ones.This willingness to implement newtechnologiesis being triggered by the needto catch up for theyears of restrained investments, and supported by the positive economic

situation of the chemical industry worldwide.Equipment and service suppliers to the process industry, the key targetgroup of ACHEMAs exhibitors clientele, have read the signs of the timesand book exhibition space well in advance to get their prime choice.

Innovative concepts for the use ofresources and energyWhile it is still too early to identify topical trends on the part of the ex-hibitors it is evident that innovative concepts for the use of resources andenergy, the issue of this years special show, will, in a wider sense, runthrough ACHEMA 2009 like a thread.The spectrum of exhibitors targetedby the special show itself includes industrial (white) biotechnology aswell as plants for the production of biofuels and biogas, biorefineries, bio-

plastics and biocomposites.The field of photovoltaics with its special ma-terials and applications as well as photobioreactors, solar-chemicalprocesses, chemical andthermal processes arealso focal points of thespe-cial show.Independant from that, and based onthe feedback from DECHEMAs scien-tific community and networking, thekey issues of the conference programhave in the meantime been defined asfollows:

General Topics New Reaction Pathways and Ad-vanced ReactionTechnology

Mixing and Separation Technology

Plant Components: Apparatus,Piping, Reactor Plant Controlling: Systems, Field De-

vices and Concepts Processes and Apparatus for Pharma-

ceutical Production Laboratory and Analysis Techniques

SafetyMaterials for Apparatus and Plants

Special Sessions Industrial Biotechnology Chemistry and Biotechnology of Renewable Materials and EnergyResources Chemistry and Process Engineering for Power Supply Food Processing Formulation Technologies Gas Separation by Membranes High-throughput Technology Industrial Water Technologies Integrated Energetic Use of Biomass, RDF and Waste Ionic Liquids in Process Engineering Laboratory Reactors to Study Catalysis and ProcessesMaterials and Energy Flow Analysis

Microchemical EngineeringMinimization of CO

2Emissions

Modelling in Process Engineering Status and Perspectives Nanotechnology/Nanomaterials Process Analytical Technologies Process Intensification Separation Technology Smart Packaging Solids Process EngineeringWaste Treatment

ACHEMA conference applications are requested in form of asingle pageabstractvia http://www.achema.de/congress(max. 200kB). Lecture time is 20 minutes; the congress lan-

guage is English.DECHEMAs Congress Office can also be reached via e-mail forfurther information at [email protected], or by telephone+49/(0)69/7564-333. Application deadline is August 31,2008.

Meeting pointof experts

ACHEMA 2009:Brisk exhibitors demand and exciting

conference topics

N e w sWORLDWIDE

THOMAS SCHEURING

Dr. Thomas Scheuring,

Head of Exhibition Congresses, DECHEMA e.V.,

Frankfurt am Main/Germany

Just browse through www.achema.deor simply send an e-mail [email protected] the official brochure AnnouncementACHEMA 2009 which comes hot off thepress with all relevant details for ex-hibitors, congress attendees and visitors.And last but not least: While exhibition

space is still available in each exhibitiongroup it is evident that options aregettingscarce the longer you wait. So save disap-pointments and book your exhibitionbooth now!

You need more information?



21/21

Editorial Staff

Editor-in-Chief: Gerd Kielburger (+49-9 31) 4 18-25 36,[email protected]

Editor: Dr. Jrg Kempf (+49-9 31) 4 18-21 73,[email protected]

Editorial assistant: Gabriele Ilg (+49-9 31) 4 18-21 07,[email protected]

Editorial office: Vogel Industrial MediaMax-Planck-Str. 7/9, 97082 Wuerzburg,GermanyFax (+49-9 31) 4 18-27 50, [email protected],www.process.de, www.process-worldwide.com

Layout: Dieter Kansog

Production: Karin Weienberger (+49-9 31) 4 18-22 57

Publisher

Publishers address: Vogel Industrie Medien GmbH & Co. KG,Max-Planck-Str. 7/9, 97082 Wuerzburg, Germany(+49-931) 418-0, Fax (+49-9 31) 4 18-27 50A Company of Vogel Business Media

General Manager: Claus Wstenhagen

Advertising Manager: Reiner ttinger (+49-9 31) 4 18-26 13(responsible for the advertising section)[email protected]

Copyright: Vogel Industrie Medien.All rights reserved. Reprints, digital processingof all kinds and reproduction only by written permission of the publisher.

is a special issue of

Industrial Media

N e w sWORLDWIDE

I N T E R N AT I O N A L C O N F E R E N C E SO R G A N I Z E D B Y D E C H E M A

March 1011, 2008: High Pressure meets Advanced Fluids,Aachen/GermanyMarch 1011, 2008: International Workshop Molecular Modelingand Simulation in Applied Material Science, Frankfurt am Main/GermanyApril 24, 2008: 11th Annual Conference of the European BiosafetyAssociation, Florence/ItalyApril 2225, 2008: EuroPACT, 1st European Conference onProcess Analytics and Control Technology, Frankfurt am Main/GermanyMay 2528, 2008: 47. Tutzing Symposium: Modelling andengineering of complex systems from molecular assembles tobiological networks, Tutzing/GermanySeptember 710, 2008: 7th European Symposium onBiochemical Engineering Science (ESBES), Faro/PortugalSeptember 711, 2008: EUROCORR 2008 European CorrosionConference, Edinburgh/UKSeptember 2124, 2008: ISPPP 2008 28th InternationalSymposium on the Seperation of Proteins, Peptides and Polynucleotides,Baden-Baden/GermanySeptember 28October 1, 2008: Green Solvents Progress inScience and Application, Lake Constance, Friedrichshafen/GermanySeptember 28October 2, 2008:5th International Conference on Combinatorial and High-ThroughputMaterials Science,Kloster Seeon/GermanyOctober 810, 2008: Conference on Metalorganic Frameworks andOpen Framework Compounds,Augsburg/Germany

Further Information:DECHEMA e.V., Congress OfficeTheodor-Heuss-Allee 2560486 Frankfurt am Main/GermanyTel. +49 (0)69 7564-129/-333/-249Fax +49 (0)69 7564-176E-mail [email protected] www.dechema.de

asecos GmbHwww.asecos.com . . . . . . . . . . . . . . . 18

AUMA RIESTER GmbHwww.auma.com. . . . . . . . . . . . . . . . . 3

C. Otto Gehrckens GmbHwww.cog.de. . . . . . . . . . . . . . . . . . . 15

Carl Padberg Zentrifugenbau GmbHwww.cepa-zentrifugen.com . . . . . . . 23

Dperthal Sicherheitstechnik GmbHwww.dueperthal.com . . . . . . . . . . . . . 7

Evonik Industries AGwww.evonik.com . . . . . . . . . . . . 2nd cp

Hess GmbHwww.resale-germany.com. . . . . . . . . 13

HosokawaAlpineAGwww.alpinehosokawa.com. . . . . . . . 19

i-fischer-Engineering GmbHwww.i-fischer.com . . . . . . . . . . . . . . 17

ILUDEST Destillations- anlagen GmbHwww.iludest.com . . . . . . . . . . . . . . . 16

Maag Pump Systems Textron AGwww.maag.ch . . . . . . . . . . . . . . . . . . 4

MICRODYN-NADIR GMBHwww.microdyn-nadir.com. . . . . . . . . 21

Pieralisi spawww.pieralisi.com . . . . . . . . . . . . . . 15

Schmitt-Kreiselpumpen GmbHwww.schmitt-pumpen.de . . . . . . . . . 15

Seybert & Rahier GmbHwww.sera-web.de. . . . . . . . . . . . . . . . 9

WIKA Alexander Wiegand GmbHwww.wika.de. . . . . . . . . . . . . . . . . . 11

W

S

P

M

I

H

E

D

C

AADVERTISERS INDEX

achema+world+wide+news+1 2008

Documents